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Summary
 Background Medulloblastoma, a primitive neuroectodermal tumour growing in the cerebel-
lum, is one of the most sensitive childhood brain tumours to radiation therapy. 
The most common malignant CNS tumour of children is medulloblastoma with 
an overall incidence among children aged 0–19 years of 16–20% of all paediat-
ric brain tumours. Radiotherapy is an essential method of treatment for these 
tumours, but surgery is the primary treatment of choice in medulloblastoma. 
Postoperative radiation therapy has a signiﬁ cant impact on local control and 
overall survival.
 Aim Medulloblastoma is the most common malignant brain tumour of children. The 
tumour is sensitive to chemotherapy and radiotherapy. Radiotherapy is an essen-
tial method of treatment for these tumours, but surgery is the primary treatment 
of choice in medulloblastoma.
 Materials/Methods Between January 1997 and March 2005 there were in this study post-operatively 
irradiated a total number of 33 paediatric patients aged under 15 years (median 
age 6.6 years) with medulloblastoma. All tumours were histologically proven and 
were located infratentorially in the posterior fossa. All of the patients were irradi-
ated with a dose of 24–36Gy to the whole craniospinal axis and boost with confor-
mal therapy restricted to the tumour bed to the total dose of 50–54Gy (30–36Gy 
“high risk”, 24–30Gy “standard risk” group). 26 patients (78%) received chem-
otherapy. Patients with craniospinal irradiation were placed in the supine posi-
tion and ﬁ xed by a vacuum-form body immobilizer and head mask. Irradiation 
was performed using standard fractionation (5 fractions per week) with a single 
dose of 1.5–1.8Gy for craniospinal axis by photon beam (6MV) of the linear ac-
celerator.
 Results The median overall survival for the whole group was 55.3 months. The median 
disease-free survival was 20.6 months. The overall survival rate at 5 years was 41%; 
8 patients (24%) died. No relationship was found between survival and age, sex 
or tumour size. Endocrine deﬁ cits occurred in 30% (8 patients of the group were 
hypothyroid, growth retardation occurred in 7 patients).
 Conclusions Results of overall and disease-free survival and side-effects of the technique of 
craniospinal axis irradiation in supine position are comparable with results of 
the technique in prone position.
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BACKGROUND
Medulloblastoma, a primitive neuroectoder-
mal tumour growing in the cerebellum, is one 
of the most sensitive childhood brain tumours 
to radiation therapy. The most common malig-
nant CNS tumour of children is medulloblast-
oma with an overall incidence among children 
aged 0–19 years of 16–20% of all paediatric brain 
tumours. Radiotherapy is an essential method 
of treatment for these tumours, but surgery is 
the primary treatment of choice in medullob-
lastoma. Postoperative radiation therapy has a 
signiﬁ cant impact on local control and overall 
survival. Meta-analyses of patients with medul-
loblastomas irradiated postoperatively revealed 
prolongation of the 5-year survival rate in 60% 
of cases. Craniospinal irradiation is necessary in 
the treatment of medulloblastoma, although it 
results in signiﬁ cant long-term sequelae, partic-
ularly in young children. The impact of techni-
cal quality of radiation therapy on survival was 
recently considered [1–7].
AIM
Medulloblastoma is the most common malignant 
brain tumour of children. The tumour is sensitive 
to chemotherapy and radiotherapy. Radiotherapy 
is an essential method of treatment for these tu-
mours, but surgery is the primary treatment of 
choice in medulloblastoma.
MATERIALS AND METHODS
Between January 1997 and March 2005 a total 
number of 33 paediatric patients aged under 
15 years (median age 6.6 years) with medullob-
lastoma were irradiated in the Department of 
Radiation Oncology, Masaryk Memorial Cancer 
Institute in Brno. Surgical resection was per-
formed in all patients. All tumours were histo-
logically proven and were located infratentorial-
ly in the posterior fossa. Detailed characteristics 
of the patients are shown in the table (Table 1). 
All of the patients were irradiated with a dose of 
24–36Gy to the whole craniospinal axis and boost 
with conformal therapy restricted to the tumour 
bed to the total dose of 50–54Gy (30–36Gy “high 
risk”, 24–30Gy “standard risk” group). 26 patients 
(78%) received post-operative chemotherapy.
Deﬁ nition of planning target volume for cranios-
pinal irradiation: 1. Whole brain: this volume en-
compasses the whole brain with 1cm safety mar-
gin. The lower limit of the frontal area must be 
5mm below the frontal sinus and 1cm below the 
temporal lobes. A margin of 5mm is required in 
front of vertebra C2. 2. Spinal axis: in the inferi-
or limit must be included vertebrae S2–4. A lateral 
safety margin of 5mm is required regarding the 
lateral process. The ICRU 50 point of the whole 
brain is in the centre of the target volume and 
of the spinal axis is in the centre of the medullar 
cord. Treatment planning was based on a series 
of about 30–40 consecutive CT slices. The use of 
three-dimensional treatment planning is a stand-
ard therapeutic method.
In whole brain and cervical spine irradiation (with 
the caudal border between C3–C4 vertebrae), two 
opposite lateral ﬁ elds ere chosen with shielding 
blocks of the eye bulbs; the spinal cord was irra-
diated with two direct posterior ﬁ elds (Figure 
1). After reaching 33% and 66% of the planned 
dose, the size and the borders of the adjacent 
ﬁ elds in the area of the spine were modiﬁ ed 
(Figure 2). It was necessary to include the whole 
vertebral volumes in the irradiated volume in or-
der to diminish the risk of postirradiation scol-
iosis of the spine. Patients were placed in the su-
pine position and ﬁ xed by a vacuum-form body 
immobilizer and Orﬁ t head mask (Figure 3). Use 
of the vacuum-form body immobilizer caused a 
1–2% decrease of applied depth dose. This irra-
diation technique caused a tolerable increase in 
the superﬁ cial skin dose with regard to the to-
tal dose applied to the planning target volume. 
Irradiation was performed using standard frac-
tionation (5 fractions per week) with a single 
dose of 1.5–1.8Gy for craniospinal axis by pho-
ton beam (6MV) of the linear accelerator. It was 
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necessary to determine exactly the position of 
the child on the treatment table with the help 
of laser beams and the optical pointer of the ir-
radiation device.
A value a<0.05 was taken as a universal indica-
tive limit for statistical signiﬁ cance in all analyses. 
Standard descriptive statistics were used to express 
differences among subgroups of cases, namely ro-
bust statistics like median and MIN/MAX values . 
Gender male 66.7%
female 33.3%
Age median 8.7 years
mean 8.8 years
Children under 3 years 15.2%
Extent of resection total 42.4%
subtotal 39.4%
less than subtotal 18.2%
Chang T T1 3.0%
T2 9.1%
T3a 39.4%
T3b 30.3%
T4 18.2%
Chang M M0 69.7%
M1-3 30.3%
Histological subtype “classic” 69.7%
desmoplastic 18.2%
large cell 6.1%
unknown 6.1%
Table 1. Clinical characteristics of children with medulloblastoma.
Figure 1. Modifi ed technique of craniospinal irradiation using two 
opposite lateral fi elds (individual shielding blocks of the eye bulbs 
and the face part of the skull (a), and two direct fi elds (b), using 
the asymmetric jaws. Linear accelerator, X-ray, 6MV (c).
Figure 2. The radiation fi elds – scheme of changes of size. After 
reaching 33% and 66% of the planned dose, the size and the borders 
of the adjacent fi elds in the area of the spine were modifi ed.
Figure 3. Supine position and fi xed by a vacuum-form body 
immobilizer and Orfi t head mask for patients with craniospinal 
irradiation.
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Standard univariate statistical techniques were 
used to test differences between chosen subgroups 
of patients: M-L chi-square test for binary or ordi-
nal categorical variables and Kruskal-Wallis rank 
test continuous scales. Kaplan-Meier product-lim-
it method was applied to describe survival rates 
and to discriminate them among two or more sub-
groups. Peto-Prentice generalized log-rank test was 
used as a comparative statistical test [8,9].
RESULTS
The prescribed dose of irradiation was delivered 
to all patients; dose reduction was not necessary 
in any case. In March 2006 (date of evaluation) 
17 out of 33 patients (51.5%) remain without any 
sign of disease; one patient has local relapse. Six 
patients (18%) present signiﬁ cant neurological 
symptoms. Local relapse occurred in 3 patients 
(9%). Local relapse with spinal metastases was 
described in 10 patients (30%) and metastases 
without CNS in two patients (Table 2).
Radiotherapy was well tolerated. Skin reactions 
were mild in most patients: WHO grade I in 33 
(100%) patients and grade II in 8 (24%) patients 
(in areas of ears). Within three months after the 
completion of radiotherapy these reactions disap-
peared. The gastrointestinal and haematological 
toxicities were mild to moderate in all patients 
(WHO I-II gr.), but none grade III. Leucopenia 
grade I was in 70%, grade II in 18%, trombocyto-
penia grade I in 35%, diarrhoea grade I in 47% 
and grade II in 23%, nausea in 36%.
The median overall survival for the whole group was 
55.3 months (Figure 4). The median disease-free 
survival was estimated as 20.6 months. 8 patients 
(24%) died; these patients died of local failure. 
Overall survival stratiﬁ ed according to radiother-
apy dosage on craniospinal area is better for dose 
24Gy (“standard risk” group) (Figure 5). Graphical 
comparison of event-free survival and overall surviv-
al speciﬁ cally showed prolonged overall survival in 
the region of early risk events (early relapses and/or 
progression that occur in the early phase of follow-
up). In our study the statistical difference in surviv-
al rate between standard and high-risk patients with 
medulloblastoma and association between dose on 
CS (Gy) and therapeutic response was not shown 
(Table 3). No relationship was found between sur-
vival and age, sex or tumour size. Endocrine deﬁ -
cits occurred in 30% (10 patients in all: 8 patients 
of the group were hypothyroid, 7 patients are in 
growth retardation, 2 patients needed growth hor-
mone replacement therapy, 1 patient had early pu-
berty). The association between dose on CS (Gy) 
and incidence of subsequent chronic effects is 
shown in the table (Table 4).
DISCUSSION
Postoperative morbidity has been signiﬁ cantly re-
duced by the introduction of microsurgical tech-
niques. Based on previous retrospective studies, 
showing a rather high risk of local recurrence or 
cerebrospinal ﬂ uid dissemination, postoperative 
radiotherapy is recommended after surgical treat-
ment of medulloblastomas [2–4].
Until recently, the standard care for patients with 
average risk disease consisted of postoperative ra-
diotherapy with a dose to the craniospinal axis 
of 35–36Gy followed by a boost to the entire pos-
terior fossa to a total dose of 54–55Gy. In mul-
ti-institution studies, such treatment results in 
long-term event-free survival in approximately 
60–65% of patients. Two cooperative groups test-
ed the efﬁ cacy of reduced dose in radiotherapy 
with average risk medulloblastoma. In the SIOP 
II study with double randomization patients with 
all stages were eligible for craniospinal irradia-
tion and were randomized between standard dose 
(35Gy) and reduced dose (25Gy). Overall, event-
free survival at 5 years for patients who received 
standard dose CSI with or without chemotherapy 
Without sign of disease 51.5% (17 patients)
Local relapse 9% (3 patients)
Local relapse + spinal 
metastases 30% (10 patients)
Metastases without CNS 6% (2 patients)
Overall survival (median) 55.3 months
Disease-free survival 
(median) 20.6 months
Overall survival rate (5 y) 41%
Dead 24% (8 patients)
Neurological symptoms 18% (6 patients)
Endocrine defi cits 30% (10 patients)
 hypothyreosis 24% (8 patients)
 growth retardation 21% (7 patients)
 defi cit of growth hormone 6% (2 patients)
Table 2. Results of treatment in children with medulloblastoma 
(33 patients).
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was 60% as compared with 69% for those treat-
ed with reduced dose CSI [10].
The Paediatric Oncology Group (POG, 8631) 
and Children’s Cancer Study (CCG-923) during 
1986–1990 were randomized also between stand-
ard craniospinal radiotherapy to a dose of 36Gy 
and to a dose 23.4Gy. Event-free survival at 5 years 
for patients who received standard dose was 67% 
and 52% for patients with reduced dose [11]. In 
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Figure 4. Kaplan-Meier curves of overall and disease-free survival 
(months) of 33 patients with medulloblastoma.
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Figure 5. Overall survival stratifi ed according to radiotherapy 
dosage on craniospinal area.
Dose on CS Categories of therapeutic response
Primary data Complete remission Partial remission Progression
24Gy N=5 N=1 N=1
30Gy N=6 N=4 N=0
36Gy N=2 N=5 N=1
Aggregated categories* Complete remission Partial remission + Progression
24Gy N=5 (71.4%) N=2 (28.6%)
>2 Gy N=8 (44.4%) N=10 (55.6%)
Table 3. Association between dose on CS (Gy) and therapeutic response.
*  Data were aggregated in order to document most visible asymmetry in the reached categories of therapeutic response. Although not 
exactly statistically signifi cant (p=0.221; M-L Chi-square test), the accumulation of CR category after dosage of 24Gy is apparent.
Dose on CS
Incidence of chronic eff ects 
Total
According to type of eff ect 
Growth problems Hypothyreosis 
24Gy N=3 (42.9%) N=1 (14.3%) N=2 (28.6%)
30Gy N=5 (45.5%) N=4 (36.4%) N=3 (27.3%)
36Gy N=3 (37.5%) N=2 (25.0%) N=3 (12.5%)
Statistical diff erence1 p=0.941 p=0.568 p=0.886
Table 4. Association between dose on CS (Gy) and incidence of subsequent chronic eff ects.
* Statistical signifi cance of diff erences among diff erent dosage categories (M-L Chi-square test).
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the PNET-3 study (1992–2000) there was more 
intensive pre-radiotherapy chemotherapy. CSI 
was 35Gy. At 3 years, event-free survival for pa-
tients treated with radiotherapy alone was 64.2% 
as compared with 78.7% for patients treated with 
pre-radiotherapy chemotherapy [2,12].
Overall ten-year survival rates in series that include 
patients with all stages of disease are approximate-
ly 40–50%. Factors that correlate with outcome in-
clude the presence or absence of cerebrospinal 
ﬂ uid seeding at diagnosis, the completeness of sur-
gical resection, and age at diagnosis [2,13,14].
Age at diagnosis is also of prognostic value. In 
general, the outcome of children aged over 3 
years is signiﬁ cantly better than for younger pa-
tients. Children younger than 3 years have mark-
edly poorer outcomes. Younger children more 
commonly present with metastatic disease and 
they do not commonly receive conventional dos-
es of craniospinal radiotherapy [15,16]. In our 
study differences in survival rate for patients with 
medulloblastoma between survival and age, sex 
or tumour size were not observed.
Another important factor that inﬂ uences treat-
ment results is the radicality of the surgical in-
tervention. In their long-term study Chiu et al. 
reported 61% of the patients being well without 
relapse after complete resection, compared to 
only 37% of the patients surviving without symp-
toms of disease after partial tumour resection 
[17]. In our study differences for patients with 
complete and partial resection were not shown.
The risk of chronic postirradiation changes can 
be diminished by hyperfractionated radiothera-
py (twice a day at a lower dose), but this method 
of irradiation has not been routinely used so far. 
Hyperfractionated irradiation, however, increas-
es the risk of severe acute and subacute chang-
es in the brain tissue (haemorrhages, necroses). 
Hyperfractionated radiation has not been shown 
to hold any beneﬁ t over conventionally fraction-
ated radiation. [18,19].
Intensity modulated radiation therapy (IMRT) 
is a modern conformal technique that employs 
energy beams shaped by dynamic multi-leaf col-
limators to deliver radiation to a tightly deﬁ ned 
area, with the goal of reducing normal tissue ra-
diation exposure. One of the main beneﬁ ts of 
IMRT use in therapy of medulloblastoma is avoid-
ance of cochlear irradiation and the resultant 
hearing loss [20].
Patients are usually treated in the prone posi-
tion, which is not as comfortable, reproducible 
or as easily maintained as the supine position. 
To minimize anaesthesia-related risks, irradia-
tion in supine position would be preferable to 
standard prone position. Treatment in supine 
position would be more comfortable for adult 
patients as well [21–24].
The supine position provides in addition numer-
ous advantages. For young children (less than 6–
7 years of age) who require craniospinal irradi-
ation with intubation (anaesthesia) irradiation 
only in the supine position is workable. Patients 
are more comfortable, and the treatment position 
is more reproducible and much better tolerated 
than the prone technique. The use of CT simu-
lation signiﬁ cantly decreases the simulation time 
and also reduces daily treatment time [25].
The cognitive deﬁ cits induced by cranial irradia-
tion are delayed in onset, then progressive over 
3 to 5 years and vary with neuro-developmental 
status, radiation dose and volume. Endocrine 
deﬁ cits occurred in 61%, neurological complica-
tions in 72%, and signiﬁ cant school problems in 
72%. All patients had signiﬁ cant deﬁ cits in neu-
rocognitive functioning: attention and process-
ing speed was impaired in 79%, learning and 
memory in 88%, language in 56%, visual per-
ception in 50%, and executive functions in 64% 
[26]. In our study these treatment sequelae were 
not evaluated.
Growth failures are the most common form of 
neuroendocrinologic dysfunction as sequelae of 
craniospinal irradiation. Another common ef-
fect of craniospinal irradiation is hypothyroidism 
[27,28]. The numbers of growth failures and hy-
pothyroidism in our study were comparable and 
hearing deﬁ cits were not shown.
In the study of Oyharcabal-Bourden et al. the 5-
year recurrence-free survival rate of patients with 
all optimal quality controls of histology, radiolo-
gy and radiotherapy was 71.8±10.5%. In terms of 
sequelae, 31% of patients required growth hor-
mone replacement therapy and 25% required 
special schooling [29].
CONCLUSIONS
Irradiation of the craniospinal axis forms part of 
the treatment of a number of malignant diseases. 
Patients are usually treated in the prone position 
which is not as comfortable, reproducible or as 
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easily maintained as the supine position. Acute 
skin, haematological and gastrointestinal reac-
tions were comparable with those in patients irra-
diated in the prone position. To minimize anaes-
thesia-related risks irradiation in supine position 
would be preferable to standard prone position. 
Treatment in supine position would be more com-
fortable for adult patients as well. These results 
(results of overall and disease-free survival) and 
side-effects ofthe technique of craniospinal axis 
irradiation in prone position are comparable with 
results of the technique in supine position.
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